Abstract: The present invention discloses a salt derivative of 1-(3-methanesulfonamidobenzyl)-6-methoxy-7-benzyloxy-1,2,3,4-tetrahydroisoquinoline. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL.
Type:
Grant
Filed:
August 30, 2017
Date of Patent:
June 9, 2020
Assignees:
China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry
Abstract: Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, Q, X and n are defined as in the description. Also disclosed are a method for preparing the compounds of formula I, a composition containing the compounds, and the uses of the same in the preparation of medicaments for regulating blood lipid and/or preventing gallstone. The compounds of formula I disclosed in the present invention have stability in vitro, good solubility in the pharmaceutical organic solvents and favorable bioavailability in animals.
Type:
Grant
Filed:
June 25, 2012
Date of Patent:
October 1, 2019
Assignees:
Shanghai Institute of Phamaceutical Industry, China State Institute of Pharmaceutical Industry
Inventors:
Zhenpeng Yu, Gouping Wang, Zhen Zhang, Minyu Liu, Xiaoling Huang, Ying Liu, Lin Xiao, Li Cai, Xuejun Wu, Yifang Deng, Mianli Pan, Renhai Chen, Shenrong Tang, Quanhai Liu
Abstract: Disclosed are a method for preparing a dabigatran etexilate intermediate, and an intermediate compound. The method for preparing a dabigatran etexilate intermediate 4 comprises: reacting a compound 3 with a C1-C3 alkyl alcohol solution of methylamine in an organic solvent, wherein, X=chlorine, bromine, or iodine. Also disclosed are an intermediate compound 3 and a preparation method thereof. The method for preparing a dabigatran etexilate intermediate of the present invention has the advantages of simple process, easy operation, high yield, and easy purification, thus being suitable for industrial production.
Type:
Grant
Filed:
July 3, 2014
Date of Patent:
October 30, 2018
Assignees:
SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Abstract: Disclosed are a platinum (II) compound, a preparation method therefor, and a pharmaceutical composition and an application thereof. The preparation method comprises the following steps: enabling dihydrate diammine platinum nitrate (4) to react with the carboxylate ligand derivative (5) in water, to produce a platinum (II) compound. Also provided are an application of the platinum (II) compound in preparation of an antitumor drug, and a pharmaceutical composition. The pharmaceutical composition contains an active component and a medicinal carrier, the active component containing the platinum (II) compound, and the mass percentage of the active component being 0.1%-95%. The platinum (II) compound of the present invention is well water-soluble, low toxic, easily prepared, and efficient in antitumor activity.
Type:
Grant
Filed:
March 19, 2014
Date of Patent:
May 16, 2017
Assignees:
SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY
Inventors:
Baoquan Zhu, Yongzhi Shu, Jun Lin, Haifeng Hu, Quanhai Liu, Bin Zhou
Abstract: Disclosed are a platinum (II) compound, a preparation method therefor, and a pharmaceutical composition and an application thereof. The preparation method comprises the following steps: enabling dihydrate diammine platinum nitrate (4) to react with the carboxylate ligand derivative (5) in water, to produce a platinum (II) compound. Also provided are an application of the platinum (II) compound in preparation of an antitumor drug, and a pharmaceutical composition. The pharmaceutical composition contains an active component and a medicinal carrier, the active component containing the platinum (II) compound, and the mass percentage of the active component being 0.1%-95%. The platinum (II) compound of the present invention is well water-soluble, low toxic, easily prepared, and efficient in antitumor activity.
Type:
Application
Filed:
March 19, 2014
Publication date:
July 7, 2016
Applicants:
SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY
Inventors:
Baoquan ZHU, Yongzhi SHU, Jun LIN, Haifeng HU, Quanhai LIU, Bin ZHOU